Read Jonathan Emord’s October 12, 2016 article in the Washington Times concerning the FDA’s untenable decision to downgrade Electroconvulsive Therapy (ECT) medical devices from Class III to Class II:
The FDA’s bow to barbarism: Downgrading the brain injury risks from shock therapy is unjustified (Oct. 12, 2016) (opens in new window)
Whether evaluating a concept, performing regulatory due diligence, maintaining or prosecuting regulatory filings, or contesting adverse litigation, Emord & Associates provides exceptional counsel for all your litigation and regulatory needs.
11808 Wolf Run Lane
Clifton, VA 20124
Telephone: (202) 466-6937
Telecopier: (202) 466-6938
